Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCerillion Regulatory News (CER)

Share Price Information for Cerillion (CER)

Share Price is delayed by 15 minutes
Get Live Data
1,247.50    5.00 (0.40%)
Bid:
1,235.00
Ask:
1,260.00
Spread: 25.00 (2.024%)
Market Cap: £369.26m
CER Live PriceLast checked at - London Stock Exchange

Intraday Cerillion Share Chart

Further concentrate purchase

1 Oct 2007 07:02

Celtic Resources Holdings PLC01 October 2007 1 October 2007 Celtic Resources Holdings Plc ("Celtic" or the "Company") Celtic enters into agreement to purchase concentrates Celtic is pleased to announce that it has entered into an agreement with asubsidiary of European Goldfields Limited, Hellas Gold S.A. ("Hellas Gold"), forthe purchase of 50,000 tonnes of concentrates containing approximately 30,000 ozof gold. As announced on 22 September 2006, the Company acquired 9,000 tonnes ofconcentrate containing approximately 6,000 oz of gold, to be processed on atrial basis, by Celtic at its Suzdal BIOX(R) plant in Kazakhstan. The Companyalso announced that, if the initial shipments proved successful, it intended topurchase up to an additional 120,000 tonnes of concentrates from Hellas Gold.The Company has been very satisfied by the results of the trial and is thereforeannouncing an agreement to purchase a further 50,000 tonnes of concentrates,with shipments expected to be completed by the end of September 2009. The Company operates the only BIOX(R) plant in the FSU for the treatment ofrefractory sulphide ores and in addition to treating ore produced at its Suzdalmine, it will be utilising available BIOX(R) capacity to produce more gold. Suzdal has produced over 28,599 oz of gold in the last three months, whichincludes 11,780 oz produced in September, at an average sale price of US$718 peroz. Kevin Foo, Managing Director of Celtic, said, "We have been delighted with theresults of our initial trial to process third party concentrates at our SuzdalBIOX(R) plant. This agreement is a significant step forward in our strategy tocapitalise on our technology advantages at Suzdal and we are also looking atother third party concentrate opportunities within Kazakhstan and Russia, asmany refractory gold ores remain unexploited." Contact information: Kevin Foo / Jonathan Scott-BarrettCeltic Resources Holdings PlcTel: + 44 (0)20 7921 8800Investors@celtic resources.com Leesa Peters / Jane StaceyConduit PRTel: +44 (0)20 7429 6606 / (0)792 292 3306leesa@conduitpr.com Anthony CardewCardew GroupTel: +44 (0)20 7930 0777anthony.cardew@cardewgroup.com Strand Partners LimitedSimon RaggettStuart FaulknerTel: +44 (0)20 7409 3494 About the Suzdal BIOX(R) plant: Celtic has successfully developed the first BIOX(R) plant for treatment ofrefractory sulphide ores in the FSU at its Suzdal mine in Kazakhstan. The plantuses a sulphide oxidation process for recovering gold from refractory ores orconcentrates. The process utilises a mixed population of naturally occurringbacteria, that are present in all sulphide ores, to break down the sulphidemineral matrix, thereby liberating the occluded gold for subsequent cyanidation. The BIOX(R) process acts as an alternative to conventional processes of roastingand pressure oxidation and offers advantages of reduced capital cost, simplicityof operations, robustness and very low environmental impact. Any person who is the holder of 1 per cent. or more of any class of shares inCeltic may be required to make disclosures pursuant to Rule 8.3 of the IrishTakeover Panel Act, 1997, Takeover Rules 2001 to 2006. The Directors of Celtic accept responsibility for the information contained inthis announcement and to the best of their knowledge and belief (having takenall reasonable care to ensure that such is the case), the information containedin this announcement is in accordance with the facts and, where appropriate,does not omit anything likely to affect the import of such information. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
14th Feb 20079:32 amRNSDirectorate Change
31st Jan 20077:01 amRNSRe Joint Venture
29th Jan 20074:00 pmRNSDirector/PDMR Shareholding
2nd Jan 20079:56 amRNSEPT Disclosure
28th Dec 20062:20 pmRNSTotal Voting Rights
28th Dec 200612:29 pmRNSAdditional Listing
27th Dec 20068:46 amRNSEPT Disclosure
22nd Dec 200612:34 pmRNSCeltic Resources Holdings plc
22nd Dec 200610:42 amRNSScheme of arrangement
22nd Dec 20068:01 amRNSEPT Disclosure
21st Dec 20065:21 pmRNSDirector/PDMR Shareholding
21st Dec 20065:19 pmRNSAdditional Listing
21st Dec 20062:32 pmRNSDirectorate Change
21st Dec 200611:26 amRNSEPT Disclosure
20th Dec 20063:46 pmRNSAcquisition
20th Dec 20063:20 pmRNSResult of Court Hearing
20th Dec 20067:01 amRNSUpdate re. Arduina
19th Dec 20068:16 amRNSEPT Disclosure
15th Dec 200611:40 amRNSEPT Disclosure
14th Dec 200611:12 amRNSEPT Disclosure
13th Dec 20069:12 amRNSEPT Disclosure
7th Dec 200610:27 amRNSEPT Disclosure
5th Dec 200610:48 amRNSEPT Disclosure
4th Dec 200610:46 amRNSEPT Disclosure
1st Dec 200610:28 amRNSEPT Disclosure
30th Nov 20061:40 pmRNSResult of EGM
30th Nov 200610:25 amRNSEPT Disclosure
29th Nov 200610:21 amRNSEPT Disclosure
27th Nov 200611:35 amRNSEPT Disclosure
24th Nov 20069:20 amRNSEPT Disclosure
23rd Nov 200611:54 amRNSEPT Disclosure
22nd Nov 20067:02 amRNSSale of Olympias Concentrates
22nd Nov 20067:01 amRNSConcentrate Purchase
21st Nov 200610:02 amRNSEPT Disclosure
20th Nov 200610:45 amRNSEPT Disclosure
14th Nov 20069:40 amRNSEPT Disclosure
10th Nov 20069:32 amRNSEPT Disclosure
9th Nov 200611:21 amRNSEPT Disclosure
7th Nov 200610:07 amRNSEPT Disclosure
7th Nov 20067:02 amRNSTrading Update
7th Nov 20067:02 amRNSOffer by Celtic Resources
6th Nov 20069:01 amRNSEPT Disclosure
6th Nov 20067:43 amRNSOffer Update
6th Nov 20067:01 amRNSHolding(s) in Company
3rd Nov 20064:51 pmRNSEPT Disclosure - Replacement
3rd Nov 200610:03 amRNSEPT Disclosure
2nd Nov 200610:21 amRNSEPT Disclosure
1st Nov 200610:19 amRNSEPT Disclosure
31st Oct 200611:28 amRNSEPT Disclosure
26th Oct 200610:35 amRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.